Rofecoxib
@article{Hillson2000Rofecoxib, title={Rofecoxib}, author={Jan Hillson and Daniel E. Furst}, journal={Expert Opinion on Pharmacotherapy}, year={2000}, volume={1}, pages={1053 - 1066} }
Rofecoxib (Vioxx™, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for treatment of acute pain, fever, primary dysmenorrhea and pain and inflammation in osteoarthritis (OA). It is also being evaluated for treatment of rheumatoid arthritis and adenomatous polyps of the colon. Rofecoxib is a specific inhibitor of cyclooxygenase-2 (COX-2), thereby inhibiting prostanoid synthesis in cells that express COX-2, including inflammatory cells. As cells…
3 Citations
Identification of New Rofecoxib-Based Cyclooxygenase-2 Inhibitors: A Bioinformatics Approach
- Chemistry, BiologyPharmaceuticals
- 2020
Future in vitro and in vivo studies are needed to confirm the anti-inflammatory potential of the compounds selected here with bioinformatics approaches based on rofecoxib ligand, which showed satisfactory pharmacokinetic results related to absorption and distribution.
The System Research of the Molecular Mechanism of Quyushengxin Capsule in the Treatment of Osteonecrosis of the Femoral Head
- BiologyEvidence-based Complementary and Alternative Medicine : eCAM
- 2022
An integrated approach was used to investigate the mechanism of QYSXC in the treatment of ONFH, which contained systems pharmacology, molecular docking, and chip experiment to provide a theoretical basis for further research on the molecular mechanism.
ACQ-to-AIE Transformation by Regioisomerization of Rofecoxib Derivatives for Developing Novel Mechanochromic and Acidochromic Materials
- ChemistryJournal of Molecular Structure
- 2022
References
SHOWING 1-10 OF 68 REFERENCES
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
- MedicineJAMA
- 1999
Treatment with rofecoxib was associated with a significantly lower incidence of PUBs than treatment with NSAIDs, based on survival analysis of time to first PUB diagnosis, using Pubs that met pre-specified criteria judged by a blinded, external adjudication committee.
Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.
- MedicineClinical therapeutics
- 1999
Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans
- MedicineClinical pharmacology and therapeutics
- 1999
Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology.
- MedicineThe American journal of medicine
- 1998
Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial.
- MedicineClinical therapeutics
- 1999
Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial.
- MedicineObstetrics and gynecology
- 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
- MedicineClinical therapeutics
- 1999
Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system.
- Biology, MedicineAnnals of clinical and laboratory science
- 1998
Surprisingly, COX-2 null mice are able to mount an inflammatory response, suffering however, from kidney dysfunction and a shortened life span.
The economic consequences of NSAID-induced gastrointestinal damage.
- MedicineEuropean journal of rheumatology and inflammation
- 1993
Using study data from seven countries, the cost effectiveness of prophylactic treatment with misoprostol--a prostaglandin analogue whose efficacy has been proven in the prevention of gastroduodenal ulcers in arthritic patients treated with NSAIDs--is reviewed.
Non-steroidal anti-inflammatory drug gastropathy: causes and treatment.
- MedicineScandinavian journal of gastroenterology. Supplement
- 1996
The principal physiological mechanisms which are compromised by NSAID use are mucosal blood flow, secretion of mucus and bicarbonate and maintenance of a hydrophobic mucosal surface, and Animal data suggest that polymorphonuclear leukocytes are important for acute damage though the relevance to humans has yet to be established.